Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Selecting chemoradiation in bladder cancer
Coen, J. et al, 2018 Genitourinary Cancers Symposium, Abstract 408.
Key clinical point:
Major finding: The rate of freedom from distant metastasis at 3 years was 77.8% with twice-daily radiation plus 5-flourouracil-cisplatin and 84.0% with daily radiation plus gemcitabine.
Data source: A multicenter randomized phase 2 trial among 70 patients with muscle-invasive (cT2-4a) bladder cancer who had undergone TURBT (NRG/RTOG 0712 trial).
Disclosures: Dr. Coen disclosed that he had no relevant conflicts of interest. The trial was supported by the National Cancer Institute.
Source: Coen, J. et al, 2018 Genitourinary Cancers Symposium, Abstract 408.
Citation:
Coen, J. et al, 2018 Genitourinary Cancers Symposium, Abstract 408.